Dr. Crow has a patent pending for an interferon assay.
Systemic Lupus Erythematosus
The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-α activity and low tumor necrosis factor α levels in patients with lupus
Article first published online: 29 AUG 2008
Copyright © 2008 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 58, Issue 9, pages 2818–2823, September 2008
How to Cite
Kariuki, S. N., Crow, M. K. and Niewold, T. B. (2008), The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-α activity and low tumor necrosis factor α levels in patients with lupus. Arthritis & Rheumatism, 58: 2818–2823. doi: 10.1002/art.23728
- Issue published online: 29 AUG 2008
- Article first published online: 29 AUG 2008
- Manuscript Accepted: 2 MAY 2008
- Manuscript Received: 21 JAN 2008
- NIH. Grant Numbers: R01-AI-059893 from the National Institute of Allergy and Infectious Diseases [NIAID], T32-AR-07517
- Alliance for Lupus Research
- Mary Kirkland Center for Lupus Research
- Lupus Research Institute
- NIAID Clinical Research Loan Repayment. Grant Number: AI-071651
- Arthritis Foundation Post-Doctoral Fellowship
- Toys “R” Us Foundation
- S.L.E. Foundation, Inc
- 6Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. Arthritis Rheum 2005; 52: 2396–402., , , , , , et al.
- 7Activation of the type I interferon pathway in autoimmune thyroid disease. Arthritis Rheum 2007; 56 Suppl 9: S229., , , , , .